Nesp Biosame Likely to Be Priced at 70% of Originator as Stopgap Measure

The Ministry of Health, Labor and Welfare (MHLW) plans to price the so-called “biosame” version of the Nesp (darbepoetin alfa) renal anemia drug at 70% of the originator - just as biosimilars - as Kyowa Hakko Kirin gears up for...read more